BioCentury
ARTICLE | Politics & Policy

Survey finds Europe top alternative for Chinese life science investors amid CFIUS concerns

November 1, 2019 9:59 PM UTC

A survey of Chinese investors revealed broad concern about U.S. restrictions on foreign investment in the life sciences that is diverting Chinese investments to other countries, with Europe cited as the top alternative for investment.

Sixty percent of respondents said they and their peers are “much less active” in China-to-U.S. life sciences and/or biotech investment this year, with 30% calling Chinese equity investment in U.S. biotech “mission impossible,” according to the October survey by L.E.K. Consulting. The survey polled 30 Chinese investors focused on pharma, medical technology and healthcare services and technology. ...